TITLE:
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.

CONDITION:
Carcinoma, Non-Small-Cell Lung

INTERVENTION:
ALIMTA

SUMMARY:

      The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and
      Carboplatin on you and your non-small cell lung cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  You have a diagnosis of non-small cell lung cancer.

          -  You have received no prior chemotherapy.

          -  You have at least one measurable lesion.

          -  You have an adequate performance status.

          -  You are at least 18 years of age.

        Exclusion Criteria:

          -  You have previously received chemotherapy for your lung cancer.

          -  You have received radiation within the last 30 days.

          -  You have active infection or other serious condition.

          -  You have brain metastasis.

          -  You have recently lost a significant amount of weight.
      
